CALGARY, May 19 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following submission to the U.S. Food and Drug Administration (FDA) for review, the Company is initiating a U.S. Phase I study of REOLYSIN(R) in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer (REO 022). The principal investigator is Dr. Sanjay...
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GETA.OB) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s request for “Fast Track” designation of tesetaxel for treatment of patients with advanced gastric cancer. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.
Fast Track designation is designed to facilitate...
Medical News Today
Article Date: 23 Oct 2009 - 3:00 PDT
Cancer patients don't have time to waste, yet many must endure a tedious process of elimination as physicians try several different treatments until identifying the one that is most effective against their particular type of tumor. Now researchers at the University of Virginia Health System have developed a breakthrough method that could one day eliminate this trial and error approach to treating many cancers.
National Cancer Institute
NCI Cancer Bulletin
September 22, 2009 • Volume 6 / Number 18
Many herbs, dietary supplements, and even vitamins are suspected of interfering with chemotherapy and radiation therapy, and doctors now routinely advise patients who are undergoing cancer treatment to avoid taking these products.
At the same time, cancer researchers have been intrigued by the potent and beneficial biological activity shown by some natural products...
New research details drug therapies in 2009 in Therapeutic Advances in Medical Oncology, published by SAGE
Los Angeles, London, New Delhi, Singapore and Washington DC (August 21, 2009) – Colorectal cancer (CRC) is the second leading cause of cancer-related death in the Western world. Fortunately physicians today have an abundance of drug therapies available to improve survival...
